Combination of antiangiogenic RAD001 and ionizing radiation in therapy of malignant tumors

被引：0
|
作者：
Manegold, Philipp [1 ]
Paringer, Carmen [1 ]
Kulka, Ulrike [1 ]
Wilkowski, Ralf [1 ]
Jauch, Karl-Walter [1 ]
Guba, Markus [1 ]
Bruns, Christiane J. [1 ]
机构：
[1] Univ Munich Grosshadern, Munich, Germany
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4397
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Optimization of novel antiangiogenic treatment modalities in combination with ionizing radiation
    Riesterer, O
    Oehler, C
    Zingg, D
    Vuong, V
    Broggini-Tenzer, A
    Fabbro, D
    Bodis, S
    Pruschy, M
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S152 - S153
  • [22] Phase I/II Study of Everolimus (RAD001) in Combination With Temozolomide (TMZ) in Patients With Advanced Pancreatic Neuroendocrine Tumors (NET)
    Kulke, Matthew H.
    Blaszkowsky, Lawrence
    Zhu, Andrew X.
    Florio, Sarah
    Regan, Eileen
    Ryan, David P.
    Chan, Jennifer A.
    PANCREAS, 2011, 40 (02) : 328 - 328
  • [23] Synergistic inhibition of osteosarcoma cell growth by combination of RAD001 (everolimus) and zoledronic acid
    Moriceau, G.
    Ory, B.
    Mitrofan, L.
    Brion, R.
    Charrier, C.
    Pilet, P.
    Shultz, L.
    Monkkonen, J.
    Redini, F.
    Heymann, D.
    BONE, 2009, 44 (02) : S240 - S241
  • [24] Phase I Study of Pasireotide (SOM230) in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET)
    Chan, Jennifer A.
    Ryan, David P.
    Fuchs, Charles S.
    Zhu, Andrew X.
    Abrams, Thomas A.
    Wolpin, Brian M.
    Casey, Carolyn
    Regan, Eileen
    Cavanaugh, Kristen
    Kulke, Matthew H.
    PANCREAS, 2011, 40 (02) : 325 - 325
  • [25] A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma.
    Reardon, D.
    Quinn, J. A.
    Rich, J. N.
    Vredenburgh, J. J.
    Desjardins, A.
    Sathornsumetee, S.
    Gururangan, S.
    Egorin, M. J.
    Salvado, A.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 77S - 77S
  • [26] The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
    Dragowska, Wieslawa H.
    Weppler, Sherry A.
    Qadir, Mohammed A.
    Wong, Ling Yan
    Franssen, Yannick
    Baker, Jennifer H. E.
    Kapanen, Anita I.
    Kierkels, Guido J. J.
    Masin, Dana
    Minchinton, Andrew I.
    Gelmon, Karen A.
    Bally, Marcel B.
    BMC CANCER, 2011, 11
  • [27] Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors
    Chan, Jennifer A.
    Ryan, David P.
    Zhu, Andrew X.
    Abrams, Thomas A.
    Wolpin, Brian M.
    Malinowski, Paige
    Regan, Eileen M.
    Fuchs, Charles S.
    Kulke, Matthew H.
    ENDOCRINE-RELATED CANCER, 2012, 19 (05) : 615 - 623
  • [28] Phase I trial of patupilone (P) and RAD001 in patients (pts) with advanced solid tumors
    Stein, M. N.
    Knox, B.
    Wesolowsky, E.
    Levitt, M.
    Moss, R.
    Poplin, E.
    Mehnert, J.
    Gounder, M.
    Goodin, S.
    DiPaola, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)
    Druce, M. R.
    Kaltsas, G. A.
    Fraenkel, M.
    Gross, D. J.
    Grossman, A. B.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (09) : 697 - 702
  • [30] A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma
    Desjardins, A.
    Quinn, J. A.
    Rich, J. N.
    Vredenburgh, J. J.
    Sathornsumetee, S.
    Gururangan, S.
    Friedman, A. H.
    Berg, W.
    Egorin, M. J.
    Salvado, A.
    Friedman, H. S.
    Reardon, D. A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 441 - 441
12345